Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

The British Immunological Society launches the “Celebrate Vaccines” campaign on March 26

March 25, 2020

CALL FOR EXPERTS: IUIS-Frontiers in Immunology Webinar Series on COVID-19

March 13, 2020

ASI Invite IUIS Members to Become a Member

February 26, 2020Australian and New Zealand Society for Immunology

Coronavirus disease (COVID-19)

February 24, 2020

Early Career Research Prize in Vaccinology R&D – Call for Applications!

February 10, 2020

IUIS-FAIS-SAI-AAA Immuno Algeria 2020: Challenge of Allergy in the molecular era

January 31, 2020

Congratulations to winners of the GECD Travel Award 2020

January 10, 2020

IUIS-AAI travel fellowships 2020

December 16, 2019Gender Equality and Career Development Committee (GEC), Education Committee (EDU)

We have a winner! 2019 Early Career Research Prize in Vaccinology R&D

November 29, 2019